Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.

Wang L, Chen X

Open source

DOI
10.1016/j.tranon.2026.103110
Published
2026 Nov 9
Container
Translational oncology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.tranon.2026.103110,
  title = {Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.},
  author = {Wang L and Chen X},
  year = {2026},
  journal = {Translational oncology},
  doi = {10.1016/j.tranon.2026.103110},
  url = {https://doi.org/10.1016/j.tranon.2026.103110}
}

RIS

TY  - JOUR
TI  - Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.
AU  - Wang L
AU  - Chen X
PY  - 2026
JO  - Translational oncology
DO  - 10.1016/j.tranon.2026.103110
UR  - https://doi.org/10.1016/j.tranon.2026.103110
ER  - 

APA

L, W., & X, C. (2026). Pterostilbene enhances Osimertinib sensitivity in non-small cell lung cancer through FGFR4-dependent ferroptosis.. Translational oncology. https://doi.org/10.1016/j.tranon.2026.103110

Source records